ADMA Biologics gains after refuting short seller claims

What: ADMA Biologics shares rose after the company refuted claims made by a short seller, stating that the allegations were unfounded and misleading.
Why: The short seller had accused ADMA of overstating the benefits of its COVID-19 treatment, but the company maintains that its product is safe and effective.
Signal: The stock's gain suggests that investors are responding positively to the company's defense, but the market's reaction is not a guarantee of future success.
Target: ADMA's stock price has been volatile in recent weeks, but the company's market capitalization remains above **$500 million**.
Risk: Despite the company's refutation, the short seller's claims may still pose a risk to ADMA's reputation and business prospects.